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Abstract
Background: The origin of adenocarcinomas presenting on the cervix uteri may be doubtful, i.e. whether it is of
cervical or endometrial origin, due to the overlapping morphological features. In HPV negative samples, further
tests may be needed to ascertain the nature of the tumours. We aimed to explore the use of
immunohistochemistry profiles in tissue microarrays in archived samples of adenocarcinoma (ADC) of the cervix
from Uganda that tested negative for HPV DNA.
Findings: Five commercially available antibodies were tested in tissue array sections immunostained utilizing the
avidin-biotin (AB) technique. In 26 ADC samples, HPV was detected in 13, p16 in 15 (8 in HPV positive and 7 in
HPV negative), CEA in 12, vimentin in 6, ER in 0, and PR in 2. Among the 13/25 HPV negative ADC samples, five
were positive for CEA suggesting endocervical origin, and three were vimentin positive (one had a mucinous
endocervical histological pattern and two were ADC, not otherwise specified, most likely of endometrial origin).
Conclusions: The immunoprofiles of ADC with the antibodies studied are rather nonspecific. By using
immunohistochemistry in 13 HPV negative ADC, endocervical tumour origin was suspected in five CEA positive
cases while two out of three vimentin positive samples were probably of endometrial origin, suggesting that CEA
and vimentin may be valuable in distinguishing HPV negative cervical adenocarcinomas from endometrial
adenocarcinomas.
Background
Although the role of HPV in cervical adenocarcinoma
appears well established [1-3], the nature of adenocarci-
noma arising from the cervix may be difficult to define
due to the overlapping morphological features between
cervical adenocarcinomas and endometrial adenocarci-
nomas. While endocervical adenocarcinomas express
p16 and CEA [4] and whereas endometrial adenocarci-
nomas usually showed vimentin and hormonal receptors
[5], the results may be inconclusive. However, CEA has
been reported to be expressed in both cervical and
endometrial adenocarcinomas [6], while the expression
of vimentin was noted to be weak and focal in many
endometrial adenocarcinomas [5]. An alternative view is
that some expression of these markers may reflect dif-
ferentiation (mucinous versus endometrioid) compared
to the histogenetic site of origin (endometrial versus
cervical) [7]. In order to resolve the problem, HPV test-
ing has been used in attempts to distinguish these
tumours [8]. Extending this approach, a recent study
evaluated the use of HPV DNA, p16 and hormonal sta-
tus to determine the origin of cervical tumours [9].
HPV negative adenocarcinomas in the same site may
originate either from cervical or endometrial cells. We
postulated that immunohistochemistry could be of use
in HPV negative cervical tumours from Uganda.
We aimed to explore the utility of immunohistochem-
istry profiles, i.e. the expression of p16, carcinoembryo-
nic antigen (CEA), vimentin, estrogen receptor alpha
(ER) and progesterone receptor (PR), in tissue microar-
rays in archived samples of ADC that had been tested
for HPV DNA, and in particular to assess if it would be
possible to define the tissue of origin of HPV negative
adenocarcinoma samples. This was based on the use of
CEA as a marker of endocervical ADC, vimentin and
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hormone receptors (markers more related to endometrial
ADC) and p16 as a proxy marker for HPV infection. p16
is a protein encoded by p16INK4a gene and has been
used as an indirect assay for HPV infection [10]. CEA is
an onco-fetal protein which has been touted as a useful
antibody in distinguishing between endocervical
adenocarcinoma and endometrial adenocarcinoma [6].
Vimentin is characteristically positive in endometrial ade-
nocarcinoma [5], although positivity has also been
reported in cervical adenocarcinomas [6]. ER and PR are
usually positive in endometrial adenocarcinoma and
negative in endocervical adenocarcinoma [4]. They are
used usually to exclude endocervical origin of tumours.
Materials and methods
Cervical carcinoma samples were retrieved from the
archives of the Department of Pathology, Makerere Uni-
versity, Kampala, Uganda, and were diagnosed during
the period 1968-1990. The study protocol has been
approved of Higher Degrees Research & Ethics Commit-
tee at Makerere University, Uganda.
HPV testing
The cervical carcinoma samples sections selected for
HPV testing were digested with proteinase K and the
resulting extract was used for PCR. SPF10 PCR was per-
formed using 10 μl of a 1:10 dilution of the DNA extract
in a final reaction volume of 50 μl. The amplified PCR
products were tested using probe hybridization with a
cocktail of conservative probes recognizing at least 54
mucosal HPV genotypes in a microtiter plate format for
the detection of HPV DNA. Optical densities (OD450)
were read on a microtiter plate reader. HPV DNA posi-
tive samples were subsequently analysed by HPV SPF10-
LIPA25 (version 1: produced at Labo Biomedical Pro-
ducts, Rijswijk, The Netherlands) [10,11], a reverse
hybridization technique that detects 25 high-risk and
low-risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40,
42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74).
The sequence variation within the SPF10 primers allows
the recognition of these different HPV genotypes, except
for the types 68 and 73 as their interprimer regions are
identical and cannot be distinguished on this test. After
PCR, 10 μl of the amplimers was used to perform
reverse hybridization for HPV genotype identification.
The positive hybridization on the strips is visualized as a
purple band by means of a precipitating colour substrate
on the probe site. All SPF10-LIPA25 PCR detection and
typing was performed at the facilities of DDL Diagnostic
Laboratories (DDL, Voorburg, Netherlands) and at Insti-
tut Català d’Oncologia (ICO, Barcelona). Detailed HPV
results were published elsewhere [12].
Tissue Microarrays (TMA)
Three punches (gauge 1 mm) of pre-existing paraffin
embedded tissues were obtained from each block and
then re-embedded in an arrayed master block using the
manual tissue microarrayer (Beecher Instruments, Silver
Spring MD). The punch specimens were performed in
the most representative areas of the tumours, discarding
necrosis or artefacts. Four micron paraffin sections were
cut from the TMA blocks and deparaffinised through
alcohols and xylene before immunostaining.
Immunohistochemistry (IHC)
Monoclonal antibodies included: CEA (clone B0194-
11M-P, BioGenex), p16 INK4a, p16 (clone JC8, Biocare
Medical), Vimentin (clone V9, Dako), estrogen receptor
alpha, ER (clone 1D5, Dako), progesterone receptor, PR
(clone PgR 636, Dako).
Heat Induced Epitope Retrieval (HIER) was done
using a pressure cooker as a heating device. Retrieval
solutions that were used were: Citrate buffer for Vimen-
tin, PR, ER; EDTA 10% for p16 and Saponin for CEA.
Incubation was done at room temperature for 30 min
for all the antibodies.
The Dako Autostainer universal staining system was
used with the EnVision+ Dual Link System-HRP, a two-
step IHC staining technique. This system is based on an
HRP labelled polymer which is conjugated with second-
ary antibodies.
The final reaction was done with diaminobenzydine
and slides were counterstained with hematoxylin. The
immunohistochemical stains were interpreted by one of
the authors (BL) and the results were reported as posi-
tive or negative using the following criteria for each
antibody. ER and PR were considered positive when
more than 10% of the tumour cells displayed nuclear
positive staining. p16 was considered positive/overex-
pressed if more than 75% of the tumour cells showed
cytoplasmic and/or nuclear staining, CEA was consid-
ered as positive if more than 10% of the neoplastic cells
showed cytoplasmic positive staining, and vimentin was
considered positive only when more than 20% tumour
cells displayed cytoplasmic staining. The cut-offs for
most antibodies were those used at laboratory in Barce-
lona, while the 75% for p16 was chosen because this
cut-off is both sensitive and specific for HPV related
cervical adenocarcinoma [13].
Statistical analysis
The chi-square test was used to determine significant
differences between HPV positive and HPV negative
adenocarcinomas and expression of, p16, CEA, ER, PR
and vimentin.
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Results
In total 26 samples were successfully analysed for HPV
and immunohistochemistry. In these, HPV DNA was
detected in 13/26 (50%) of ADC (Table 1). Overexpres-
sion of p16 was detected in 15/26 (57.7%) ADC. Of the
15 p16 positive cases, 8 (53.3%) were HPV positive and
7 (46.7%) were HPV negative. The reactivity was both
cytoplasmic and nuclear in positive samples.
CEA was positive in 12/25 (48%) ADC (Table 1). Of
these, seven were HPV positive and five HPV negative.
All five HPV negative and CEA positive had histological
features of endocervical ADC, suggesting endocervical
origin (Table 2). Vimentin was positive in 6/26 (23.1%)
ADC, three of them being HPV positive. Of the three
HPV negative cases, one had a mucinous endocervical
histological pattern and two were ADC not otherwise
specified (NOS), most likely of endometrial origin. ER
was not detected in any sample and PR were positive in
two samples, both HPV positive (Tables 2 and 3). Seven
ADC samples were negative for all the three markers, of
these two were HPV positive. Among the other five
samples, two had endocervical histological features,
two were serous, and one was ADC NOS. (Table 2).
The positivity for each of the immunohistochemistry
markers did not differ in HPV positive and negative
ADC (Table 3, Figure 1).
Discussion
Histological subtypes of endocervical and endometrial
ADC have some overlapping features, and poorly differ-
entiated tumours or small biopsies are difficult to
classify.
The differential diagnosis between endocervical and
endometrial ADC is a common problem in surgical
pathology, that can be approached using different
immunohistochemical antibodies, the most accepted
panel markers being CEA (as a marker of endocervical
ADC), vimentin and hormone receptors (markers more
related to endometrial ADC). HPV DNA detection by
molecular techniques has proved valuable [8]. However
in our series we found a much higher percentage of
HPV negative ADC (50%) than we expected.
As a comparison, 85% of samples were positive in the
whole series of the RIS TT study, which used similar
HPV testing methods [14]. This could probably be
explained by poor sample processing conditions in
Uganda, including problems in sample transport, type of
fixative (inconsistent use of buffered or non-buffered
formalin) and duration of fixation, leading to poor DNA
and protein preservation and consequently immunohis-
tochemistry and PCR with equivocal results.
Overexpression of p16 has been used as a surrogate
marker of high risk HPV infection [10]. Only 57.7% of
Table 1 HPV positivity and immunohistochemistry
markers in cervical adenocarcinomas (ADC)
Adenocarcinoma (ADC)
HPV positivity 48.1% (13/26)
p16 ≥ 75% 57.7% (15/26)
CEA > 10% 48.0% (12/25)
Vimentin ≥ 20% 23.1% (6/26)
ER ≥ 10% 0.0% (0/26)
PR ≥ 10% 7.7% (2/26)
Table 2 Immunohistochemistry patterns by HPV positivity in archival adenocarcinoma samples from Uganda*
HPV positive (N = 12/25) HPV negative (N = 13/25)
CEA Vimentin ER PR % with this pattern % with this pattern Histological subtype




- + - + 16.7% (2/12) 0.0% (0/13) -
- + - - 8.3% (1/12) 23.1% (3/13) Mucinous Endocervical (1)
NOS (2; probable endometrial)†
- - - - 16.7% (2/12) 38.5% (5/13) Mucinous Endocervical (1)
Mucinous Villoglandular (1)
NOS (1)†,§
Serous (2; probable endometrial)†
*Out of the 26 samples 25 were stained with all the antibodies and HPV tested.
†After immunohistochemistry and histological subtype diagnosis an endometrial origin cannot be discarded.
§No further classification because of lack of markers.
Table 3 Immunohistochemical stains by histological
subtype of cervical adenocarcinoma*
HPV + HPV- p value
p16 (+) 8/12 7/13 0.69
CEA (+) 7/12 5/13 0.53
Vimentin (+) 3/12 3/13 1.0
PR (+) 2/12 0/13 0.22
ER (+) 0/12 0/13 -
*Out of the 26 cases, histological sections stained with all the antibodies were
available in 25.
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our ADC samples were p16 positive; considering the
probable rate of false negative of 15% (the rate of false
negative in SCC) we should have about at least 25% (i.e.
57.7% + 15% = about 75%; 100% - 75% = 25%) of p16
negative ADC samples that remain unexplained. Being a
usual problem in diagnosis, the possibility of endome-
trial cancer has to be considered. Moreover, p16 itself
cannot be considered an ideal marker of HPV infection
in ADC, since many samples of HPV negative cervical
ADC have also been found to express p16 [15]. This
raises the possibility of HPV-independent mechanisms
of p16 overexpression in some cervical ADC, similar to
what has been observed in Bowen’s disease [16]. Besides,
some endometrial cancer can also display overexpres-
sion of this marker [5]. Among the 13 HPV negative
ADC, there were some features that support endocervi-
cal origin, i.e. CEA expression in five cases and the his-
tological features were in favour of endocervix in three
others although IHC results were inconclusive. Other
studies have also found that CEA is usually positive in
cervical ADC, although some samples may be negative
[4,17,18]. Three of our samples showed vimentin expres-
sion which is usually related to endometrial origin [5],
however one of them displayed a morphological pattern
suggestive of endocervical differentiation. The expres-
sion of vimentin in cervical ADC has been reported pre-
viously [6]. The absence of ER and low expression of PR
is not surprising, considering that few samples of cervi-
cal ADC are usually ER or PR positive [4].
Thus, endocervical origin seems confirmed in some
samples, endometrial cancer were suspected in four
others (two vimentin positive and two without conclu-
sive IHC results but were serous ADC) and one could
not be further classified due to lack of histological or
IHC markers.
In view of overlapping and diverge morphologic
heterogeneity of both cervical and endometrial
adenocarcinomas, the results of this study suggest that the
use of a number of markers appear useful in distinguish-
ing the two tumours in HPV negative cases. In a clinical
setting, one could use a combination of p16, CEA and
vimentin in cervical tumours to determine possible site of
origin. Another relevance of our results is in correct clas-
sification of cervical tumours for epidemiological research.
Our study has a number of strengths: only areas with-
out necrosis were sampled, the use of tissue microarray
techniques allowed uniform conditions during immuno-
histochemical staining, making the results more compar-
able, and all specimens were tested for HPV using
sensitive methods.
Our study also has some limitations, such as the small
number of samples studied, the probable variation in
the fixation of the tissues due to the fact that samples
came from different areas of Uganda, leading to loss of
antigen epitopes. In particular, estrogen and progester-
one receptors are known to be quite labile antigens.
Conclusion
In summary, our results showed overlap in expression of
p16, CEA and vimentin between HPV positive and HPV
negative cervical ADC, and suggest that some samples
among the HPV negative ADC, diagnosed as cervical
ADC, may be of endometrial origin. In our series
amongst 13 HPV negative samples, the endocervical ori-
gin seems probable in five CEA positive samples while
two vimentin positive samples are suspected to be endo-
metrial cancer. Although the number of samples studied
are too few to draw definite conclusions, it suggests that
CEA and vimentin may be of value in distinguishing
HPV negative cervical tissue from endometrial ADC.
List of abbreviations
ADC: adenocarcinoma; CEA: carcinoembryonic antigen;
ER: estrogen receptor; HIER: Heat Induced Epitope
Figure 1 Adenocarcinoma. Hematoxylin-eosin (a), p16 positive staining (b) and vimentin positive staining (c).
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Retrieval; HPV: human papillomavirus; IHC: immuno-
histochemistry; NOS: not otherwise specified; p16: cyclin
dependend kinase inhibitor 2A: tumour suppressor pro-
tein; PR: progestin receptor; PRC: polymerase chain
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